Natera, Inc. (NASDAQ:NTRA) Stock Holdings Lifted by GDS Wealth Management

GDS Wealth Management lifted its holdings in Natera, Inc. (NASDAQ:NTRA) by 245.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 12,463 shares of the medical research company’s stock after buying an additional 8,851 shares during the quarter. GDS Wealth Management’s holdings in Natera were worth $1,973,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Quarry LP increased its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the period. Versant Capital Management Inc increased its holdings in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd increased its holdings in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Performance

Shares of NTRA opened at $176.56 on Tuesday. Natera, Inc. has a one year low of $66.68 and a one year high of $183.00. The company has a 50-day moving average of $167.14 and a two-hundred day moving average of $139.03. The stock has a market cap of $23.31 billion, a price-to-earnings ratio of -100.32 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the company posted ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. On average, equities research analysts expect that Natera, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NTRA. The Goldman Sachs Group increased their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Robert W. Baird raised their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their target price on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Canaccord Genuity Group raised their target price on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $165.88.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the completion of the sale, the chief executive officer now directly owns 185,034 shares in the company, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the sale, the director now owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 268,229 shares of company stock worth $44,521,025 over the last ninety days. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.